By Jessica Wapner On 3/22/17 at 12:28 PM
Four years ago, the first curative pills for hepatitis C virus (HCV) were handed to patients. These drugs were a breakthrough for people infected with this pathogen. Lacking in serious side effects and eradicating the virus from the body in just 12 weeks, these so-called direct-acting antivirals (DAAs) offered a clean escape from this potentially fatal liver illness.
But with numerous DAAs now available—along with their long trail of clinical trial data—primary care physicians are left to navigate a crowded and confusing landscape for treating HCV. Controversy surrounding the cost of these drugs has also become a concern.
Continue reading..
But with numerous DAAs now available—along with their long trail of clinical trial data—primary care physicians are left to navigate a crowded and confusing landscape for treating HCV. Controversy surrounding the cost of these drugs has also become a concern.
Continue reading..
No comments:
Post a Comment